Table 1.
Expression of Lineage-related Markers, Stem Cell Markers, and Niche-related Antigens on ALL LSCs, CML LSCs, and Normal CD34+/CD38− Bone Marrow (BM) Stem Cells
| Expression of Marker/Antigen on CD34+/CD38− Cells in |
|||||||
|---|---|---|---|---|---|---|---|
| BCR/ABL1p210 | BCR/ABL1p190 | ||||||
| CD | Marker/Antigen | T ALL | Ph− ALL | Ph+ ALL | Ph+ ALL | CML | Normal BM |
| CD10 | CALLA | n.t. | − | + | + | n.t. | − |
| CD19 | B4 | − | + | + | + | +/− | − |
| CD22 | Siglec-2 | n.t. | +/− | + | + | n.t. | − |
| CD25 | IL-2RA | − | − | + | +/− | + | − |
| CD26 | DPPIV | − | − | + | − | + | − |
| CD43 | Leukosialin | n.t. | + | + | + | + | + |
| CD44 | Pgp-1 | n.t. | + | + | + | + | + |
| CD51 | VNRA | n.t. | − | − | − | −/+ | − |
| CD61 | VNRB | n.t. | − | − | − | − | − |
| CD90 | Thy-1 | n.t. | − | +/− | +/− | +/− | +/− |
| CD96 | Tactile | − | − | − | − | − | − |
| CD117 | SCFR/KIT | + | −/+ | − | − | + | + |
| CD133 | Prominin-1 | n.t. | +/− | −/+ | − | + | + |
| CD150 | SLAMF1 | − | − | − | − | − | − |
| CD167a | DDR-1 | n.t. | − | − | − | − | − |
| CD184 | CXCR4 | n.t. | + | + | + | +/− | +/− |
| CD243 | MDR-1 | − | − | − | − | − | − |
| CD371 | CLL-1 | n.t. | − | − | − | − | − |
| n.c. | IL-1RAP | +/− | +/− | + | +/− | +/− | − |
| n.c. | ROBO-4 | n.t. | − | − | − | +/− | n.t. |
| n.c. | HLA-DR | n.t. | + | + | + | + | +/− |
Expression of surface markers on CD34+/CD38− BM cells was determined by multi-color flow cytometry as described.30,35,36 Technical details are provided in the Supplement.
Abbreviations: ALL, acute lymphoblastic leukemia; LSCs, leukemic stem cells; CML, chronic myeloid leukemia; BM, bone marrow; CD, cluster of differentiation; n.c., not yet clustered; n.t., not tested. Score of reactivity: +, LSCs positive (median fluorescence intensity (MFI) >3) in >80% of patients; +/−, LSCs positive in 30–80%; −/+, LSCs positive in 10–29%; −, LSCs positive in <10% of patients. Antibody staining results obtained in each individual ALL patient are shown in Supplemental Table S5.